AbbVie ABBV
NYSE ABBV
$264.96 +3.13 (+1.20%)
At close: Aug 21, 2026 · 4:03 PM EDT

AbbVie (ABBV) Goodwill & Intangibles (2012 - 2026)

AbbVie (ABBV) posted quarterly Goodwill & Intangibles of $86.4 billion for Q1 2026, down 7.82% year-over-year from $93.8 billion in Q1 2025, and down 2.08% quarter-over-quarter from $88.3 billion in Q4 2025.

AbbVie (ABBV) Goodwill & Intangibles (2012 - 2026) Analysis & Trends

AbbVie (ABBV) has reported Goodwill & Intangibles for 15 consecutive years, with $86.4 billion the latest figure, recorded in Q1 2026.

  • In Q1 2026, Goodwill & Intangibles fell 7.82% year-over-year to $86.4 billion; the TTM figure through Mar 2026 stood at $86.4 billion (down 7.82% YoY), while the FY2025 annual figure was $88.3 billion, down 7.1% from the prior year.
  • Goodwill & Intangibles eased to $86.4 billion in Q1 2026 per ABBV's latest filing, from $88.3 billion in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $106.3 billion in Q1 2022 and bottomed at $36.3 billion in Q3 2025.
  • Historically, Goodwill & Intangibles has averaged $92.0 billion across 5 years, with a median of $95.0 billion in 2024.
  • Annual changes were most pronounced in 2024 — Goodwill & Intangibles grew 12.4% — and 2025, when it slumped 64.35%.
  • AbbVie's Goodwill & Intangibles stood at $99.6 billion in 2022, then dropped by 11.74% to $87.9 billion in 2023, then gained by 8.1% to $95.0 billion in 2024, then dropped by 7.1% to $88.3 billion in 2025, then fell by 2.08% to $86.4 billion in 2026.
  • Business Quant data shows ABBV's Goodwill & Intangibles at $86.4 billion in Q1 2026, $88.3 billion in Q4 2025, and $36.3 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn
10 Sanofi 55.07 Bn 47.69 Bn 10.79 Bn

Historic Data

Download Data
DateValue
Jun 30, 2026 84.66 Bn
Mar 31, 2026 86.44 Bn
Dec 31, 2025 88.28 Bn
Sep 30, 2025 36.34 Bn
Jun 30, 2025 92.67 Bn
Mar 31, 2025 93.77 Bn
Dec 31, 2024 95.02 Bn
Sep 30, 2024 101.94 Bn
Jun 30, 2024 93.63 Bn
Mar 31, 2024 95.65 Bn
Dec 31, 2023 87.90 Bn
Sep 30, 2023 90.69 Bn
Jun 30, 2023 95.09 Bn
Mar 31, 2023 97.07 Bn
Dec 31, 2022 99.60 Bn
Sep 30, 2022 100.45 Bn
Jun 30, 2022 103.85 Bn
Mar 31, 2022 106.28 Bn
Dec 31, 2021 108.33 Bn
Sep 30, 2021 109.75 Bn